A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures
University of North Carolina at Chapel Hill · Eiger Biopharmaceuticals (United States) · +3 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
683
total citations
- FWCI
- 13.85
- Percentile
- 100%
- References
- 61
Citations per year
Authors
19- KHKenneth H. Dinnon
University of North Carolina at Chapel Hill
- SRSarah R. Leist
University of North Carolina at Chapel Hill
- ASAlexandra Schäfer
University of North Carolina at Chapel Hill
- CECaitlin E. Edwards
University of North Carolina at Chapel Hill
- DRDavid R. Martinez
University of North Carolina at Chapel Hill
Topics & keywords
Topics
Keywords
- Genetically modified mouse
- Virology
- Coronavirus
- Viral replication
- Biology
- Virus
- Transgene
- Vero cell
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- UDU.S. Department of Agriculture
- NCNorth Carolina General Assembly
- NINational Institutes of HealthAwards: T32 AI007419, T32 AI007151, AI142759, AI007419, DK065988, 5P30CA016086-41, HHSN272201700036I, 5R01AI132178
- UOUniversity of North Carolina at Chapel Hill
- NCNational Cancer InstituteAwards: 5P30CA016086-41, 5P30CA016086
- NINational Institute of Allergy and Infectious DiseasesAwards: AI142759, AI007419, T32 AI007419, 5P30CA016086-41, HHSN272201700036I, T32 AI007151, 5R01AI132178
- LCLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill